Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
139
resultados
Última actualización
12/10/2025 [06:55:00]
Resumen de: WO2025212345A1
A variability metric of glucose level values of a user is calculated for each candidate sleeping time frame in a data set of glucose level values of the user obtained over time for a specified period for each day of multiple days. Each of the candidate sleeping time frames may represent a duration in which the user may have been sleeping. Execution of the programming instructions further may cause the processor to determine a mean or median of the variability metric of the glucose level values in the data set for each candidate sleeping time frame across the days in the specified period, designate a selected one of the candidate sleeping time frames that has the lowest mean or median variability metric as the sleeping time frame, and configure the pump to deliver a sleeping basal rate of the medicament for the designated sleeping time frame.
Resumen de: AU2025234254A1
SAFETY TOOLS FOR DECISION SUPPORT RECOMMENDATIONS MADE TO USERS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS Systems and method are described for determining if a decision support recommendation is to be presented to a user for treatment of a diabetic state, including receiving a plurality of input data items impacting a diabetic state of a user of continuous glucose monitor, the input data items serving as input data to a process for determining a decision support recommendation; assigning a reliability level to each of the input data items; calculating a reliability metric based on the reliability levels assigned to each of the input data items; determining a decision support recommendation based on the process and the input data and presenting the decision support recommendation to the user on a user interface only if the reliability metric exceeds a threshold. SAFETY TOOLS FOR DECISION SUPPORT RECOMMENDATIONS MADE TO USERS OF CONTINUOUS GLUCOSE MONITORING SYSTEMS Systems and method are described for determining if a decision support recommendation is to be presented to a user for treatment of a diabetic state, including receiving a plurality of input data items impacting a diabetic state of a user of continuous glucose monitor, the input data items serving as input data to a process for determining a decision support recommendation; assigning a reliability level to each of the input data items; calculating a reliability metric based on the reliability levels assigned to each
Resumen de: WO2025211978A1
The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of sensors for non-invasively checking a person's blood glucose concentration. The aim of the invention is to improve the operational efficiency of a sensor of a device for non-invasively checking a person's blood glucose concentration by reducing the set-up and configuration time required. This aim is achieved in that the claimed sensor of a device for non-invasively checking a person's blood glucose concentration comprises a housing, a light emitter and a light receiver, the inner side of the housing having a rim disposed thereon which surrounds the light receiver and separates it from the light emitter, wherein the crest of said rim has alternating projections and depressions along its length, and during the set-up and operation of the sensor, the emitter and the receiver are pressed against the pulse point on the radial artery of the arm. The technical results of the invention include: increasing the adhesive force between the rim and a person's arm by increasing the contact area between said rim and the surface of the arm; reducing the energy spent on non-invasively checking a person's blood glucose concentration; and increasing heat transfer from the sensor via the crest of the rim to the person's arm by increasing the contact area between the rim and the arm.
Resumen de: WO2025212748A1
Methods and associated devices for establishing basal rates to be programmed into a diabetic pump that periodically administers insulin to a patient. The instant disclosure also includes diabetic pumps programmed in accordance with the instant disclosure.
Resumen de: WO2025211979A1
The invention relates to medicine, and more particularly to devices for non-invasively determining a person's blood glucose concentration, and can be used in the creation of systems for diagnosing diabetes. The present device comprises a housing, and a control and display module disposed in the housing. The device further comprises a sensor, a radiation emitter, and a receiver for receiving radiation reflected from a person's tissues, the emitter and the receiver being disposed in the sensor. Disposed on the working surface of the sensor is a rim which surrounds the light receiver and separates it from the light emitter. The device is incorporated into a smartphone, with a control and data processing unit being disposed in the housing of the smartphone and the device being powered by the power supply of the smartphone. The function of a data display panel is performed by the touchscreen of the smartphone, and the sensor is disposed on the rear surface of the smartphone housing, near the upper edge thereof. The invention provides a simplified design, the possibility of visually checking the correct positioning of the sensor on a pulse point, and the possibility of keeping the device in a working state using one hand while simultaneously operating the touchscreen using a digit of the same hand.
Resumen de: WO2025209494A1
The present application provides a blood glucose monitoring method. The method comprises: determining a first early warning duration according to first blood glucose data, wherein the first blood glucose data comprises blood glucose data within a first time period, and the first early warning duration is used for performing hypoglycemia early warning. The first early warning duration is related to blood glucose fluctuation indicated by the first blood glucose data. If the blood glucose indicated by the first blood glucose data fluctuates little and changes slowly, the first early warning duration can be longer. If the first blood glucose data input into a model indicates that the blood glucose of a user fluctuates greatly and changes rapidly in historical time, the first early warning duration can be shorter. By means of implementing the described method, the electronic device can adaptively adjust the first early warning duration according to the characteristics of the blood glucose variability of a user, thereby improving the accuracy of hypoglycemia early warning.
Resumen de: US2025312239A1
Extractors and methods of extracting a medication from another medical device, such as an insulin pen. The extractor includes a syringe, a first cap having an open end adapted to be coupled to the syringe, a hypodermic needle protruding from a closed end of the first cap, and a second cap coupled at a closed end thereof to the first cap by the hypodermic needle, which extends through the closed end of the second cap and protrudes into an internal cavity of the second cap such that an internal cavity of the first cap fluidically communicates with the internal cavity of the second cap through the hypodermic needle. An open end of the second cap can be coupled to the medical device so that the internal cavity of the second cap fluidically communicates with the medical device through the hypodermic needle.
Resumen de: US2025311950A1
The present disclosure relates to a microneedle analyte sensing device for continuous monitoring of an analyte in a user's biological fluid, specifically designed for detecting ketone levels in diabetic ketoacidosis (DKA) management. The disclosed microneedle analyte sensing device utilizes dopamine (DA) molecules covalently linked to the microneedle patch's polymer structure or toluidine blue O (TBO), serving as a redox mediator for measuring the oxidation byproduct of 3-beta-hydroxybutyrate (β-HB). The sensing mechanism relies on catechol-quinone chemistry, where a pre-oxidation approach correlates sensor response to β-HB concentrations. The device comprises a plurality of microneedles on a substrate that, when applied to the skin, penetrate the stratum corneum to contact biological fluid. At least one microneedle functions as a working electrode to detect an electrochemical signal from the enzymatic reaction with the analyte, while additional microneedles serve as counter and reference electrodes to facilitate accurate electrochemical measurements.
Resumen de: US2025311946A1
An analyte monitoring device is disclosed. The analyte monitoring device comprises an analyte sensor configured to be at least partially inserted into a body of a user to detect a signal related to glucose concentration, and a sensor electronics unit electrically connected to the analyte sensor to acquire the signal, wherein the sensor electronics unit is configured to: perform communication connection with a user terminal, transmit information about the sensor electronics unit to the user terminal, receive, from the user terminal, a second security key generated based on the information about the sensor electronics unit and a first security key, perform verification of the second security key, and determine whether to maintain the communication connection based on the verification result.
Resumen de: US2025312534A1
Techniques disclosed herein relate to continuous analyte sensor measurements. In some embodiments, the techniques may involve determining that sensor-generated values indicative of a glucose level of a patient are or are to be inhibited when in a first mode. The techniques may further involve responsive to determining that the sensor-generated values are or are to be inhibited, switching operation of an infusion device from the first mode to a second mode. The techniques may further involve obtaining a blood glucose reading from the patient. The techniques may further involve responsive to obtaining the blood glucose reading, reverting operation of the infusion device to the first mode.
Resumen de: US2025312530A1
Embodiments of the current disclosure are directed toward systems, devices and methods for diabetes management. In particular, the present disclosure relates to systems, devices and methods for dispensing insulin to a patient using a miniaturized and portable patch pump.
Resumen de: US2025316375A1
Glucose prediction using machine learning (ML) and time series glucose measurements is described. Given the number of people that wear glucose monitoring devices and because some wearable glucose monitoring devices can produce measurements continuously, a platform providing such devices may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process and covers a robust number of state spaces unlikely to be covered without the enormous amount of data. In implementations, a glucose monitoring platform includes an ML model trained using historical time series glucose measurements of a user population. The ML model predicts upcoming glucose measurements for a particular user by receiving a time series of glucose measurements up to a time and determining the upcoming glucose measurements of the particular user for an interval subsequent to the time based on patterns learned from the historical time series glucose measurements.
Resumen de: US2025315997A1
Systems and methods are described that provide a dynamic reporting functionality that can identify important information and dynamically present a report about the important information that highlights important findings to the user. The described systems and methods are generally described in the field of diabetes management, but are applicable to other medical reports as well. In one implementation, the dynamic reports are based on available data and devices. For example, useless sections of the report, such as those with no populated data, may be removed, minimized in importance, assigned a lower priority, or the like.
Resumen de: US2025316358A1
Methods and associated devices for establishing basal rates to be programmed into a diabetic pump that periodically administers insulin to a patient. The instant disclosure also includes diabetic pumps programmed in accordance with the instant disclosure.
Resumen de: WO2025211546A1
This method for operating a device for providing a glucose management service comprises the steps of: acquiring discontinuous glucose data for a user which is discontinuously measured; detecting an abnormal change in glucose of the user on the basis of user data including the discontinuous glucose data; calculating a score on the necessity for continuous glucose measurement on the basis of determination information including the detection result of the abnormal change; and recommending continuous glucose measurement to the user on the basis of the necessity score of the continuous glucose measurement.
Resumen de: AU2023401746A1
Techniques for performing application-layer security and communication over primary invitation channels arc disclosed. In certain embodiments, analyte data is obtained from an analyte sensor electrically coupled to a sensor electronics module of an analyte sensor system. A secret key is established with a display device over one or more primary invitation channels. The analyte data is encrypted using the secret key. The encrypted analyte data is broadcast over the one or more primary invitation channels.
Resumen de: EP4628012A1
Provided is a sensor applicator assembly for a blood glucose monitoring including a body-attachable unit including an upper frame and a lower frame that is disposed under the upper frame and has a surface attached to a body and an applicator within which the body-attachable unit is disposed. The upper frame includes a first area and a second area disposed under the first area and in contact with the lower frame. A perimeter of an outer peripheral surface of the second area is identical to a perimeter of an outer peripheral surface of the lower frame.
Resumen de: WO2024118976A1
Embodiments disclosed herein are directed to ambulatory infusion pump systems that integrate a CGM sensor and/or a pressure sensor with an ambulatory infusion pump via a pump holder or tray that releasably holds the pump and is configured to be worn by a user, wherein the ambulatory infusion pump includes an inductive charging coil and the tray includes an inductive coil configured to be aligned with the inductive charging coil to receive power from the inductive charging coil, and wherein a processor is configured to receive and process glucose signals from the CGM sensor and pressure signals from the pressure sensor through the inductive charging coil.
Resumen de: EP4629684A1
An analyte monitoring device is disclosed. The analyte monitoring device comprises an analyte sensor configured to be at least partially inserted into a body of a user to detect a signal related to glucose concentration, and a sensor electronics unit electrically connected to the analyte sensor to acquire the signal, wherein the sensor electronics unit is configured to: perform communication connection with a user terminal, transmit information about the sensor electronics unit to the user terminal, receive, from the user terminal, a second security key generated based on the information about the sensor electronics unit and a first security key, perform verification of the second security key, and determine whether to maintain the communication connection based on the verification result.
Resumen de: US2025302614A1
Apparatuses, systems, and methods for prosthetic valves having sensor systems are disclosed. Examples of prosthetic valves include replacement heart valves for replacing the function of a native heart valve, such as a mitral or tricuspid valve. In various embodiments, replacement heart valves are provided with sensors or markers for assisting with proper placement and/or securement in the body. A replacement heart valve may include anchors for securing the replacement heart valve to native leaflets, wherein sensors and/or markers provide feedback to the physician for confirming proper placement of the anchors during the implantation procedure. Sensors may also be used to assess the function of the prosthetic valve after deployment. Sensors may also be used to monitor blood pressure, temperature, oxygen, insulin, cholesterol, and/or glucose to assess overall patient health.
Resumen de: WO2025206972A1
The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of devices for this purpose, as well as in the creation of socially-oriented systems for the early diagnosis of diabetes and associated diseases, in the form of a pendant. The aim of the invention is to improve the operational efficiency of a device for non-invasively checking a person's blood glucose concentration by reducing the set-up and configuration time required. This aim is achieved in that the claimed device for non-invasively checking a person's blood glucose concentration comprises a housing, a control and display module disposed in the housing, a sensor, a radiation emitter and a receiver for receiving radiation reflected from a person's tissues, the emitter and the receiver being disposed in the sensor and the working surface of the sensor having a rim disposed thereon which surrounds the light receiver and separates it from the light emitter. The technical results of the invention include a simplified design, the possibility of visually checking the correct positioning of the sensor on a pulse point, and the possibility of keeping the device in a working state using one hand while simultaneously operating a touchscreen using a digit of the same hand.
Resumen de: US2025303066A1
Techniques for glucose level management are disclosed. In some examples, the techniques may involve obtaining a macronutrient content associated with a meal, wherein the macronutrient content includes a first macronutrient and a second macronutrient. The techniques may further involve predicting, using a patient-specific physiological simulator that utilizes the macronutrient content, glucose amounts to be absorbed into a bloodstream of a patient as a result of consumption of the meal, wherein the patient-specific physiological simulator is configured to account for a difference in glucose level rise due to consumption of the first macronutrient compared to consumption of the second macronutrient. The techniques may further involve determining, using the patient-specific physiological simulator, a dosage of insulin to deliver to the patient based on the glucose amounts to be absorbed into the bloodstream.
Resumen de: US2025303061A1
Disclosed are techniques to establish a modified pump rate that mitigates the effects of a pump occlusion and enables a recommended dosage of insulin to be output by a pump mechanism over the course of a control cycle. In an example, the pump rate may be reduced by adding a calculated time interval between application of actuation commands to extend the amount of time over which insulin may be output by the pump mechanism.
Resumen de: US2025303063A1
A glucose control system employs adaptation of a glucose target (set-point) control variable in controlling delivery of insulin to a subject to maintain euglycemia. The glucose target adapts based on trends in actual glucose level (e.g., measured blood glucose in the subject), and/or computed doses of a counter-regulatory agent such as glucagon. An adaptation region with upper and lower bounds for the glucose target may be imposed. Generally the disclosed techniques can provide for robust and safe glucose level control. Adaptation may be based on computed doses of a counter-regulatory agent whether or not such agent is actually delivered to the subject, and may be used for example to adjust operation in a bihormonal system during periods in which the counter-regulatory agent is not available for delivery.
Nº publicación: US2025303055A1 02/10/2025
Solicitante:
TRIPLE JUMP ISRAEL LTD [IL]
Triple Jump Israel Ltd
Resumen de: US2025303055A1
Embodiments of the present disclosure are directed to miniature insulin patch pump, assistance devices (e.g., for reservoir filling and/or cannula insertion), and methods related thereto. For example, in some embodiments, a substance/drug-delivery patch pump is provided and includes a reusable part (RP) including a power source, a driving mechanism, and an electronic module, and a disposable part (DP), where the disposable part can include at least a plurality of an adhesive base, a reservoir, a dosing mechanism, and a cannula.
BOPI
Sede Electrónica
